Your session is about to expire
← Back to Search
Ceralasertib + Olaparib/Durvalumab for Cancer
Study Summary
This trial is testing a new drug to see if it works better than current treatments for solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I meet specific health, treatment history, and contraception use criteria.I don't have allergies to medications, chronic hepatitis B or C, or a weakened immune system.I haven't been treated for another cancer within the last year.My cancer has spread, worsened after treatment, and lacks ATM protein.My endometrial cancer has been confirmed with specific genetic changes.I don't have a history of specific health issues like recent major surgeries or untreated brain metastases.My cancer has spread, worsened after treatment, and requires specific tissue tests.
- Group 1: Arm III (Ceralasertib, Durvalumab)
- Group 2: Arm I (Ceralasertib Monotherapy)
- Group 3: Arm II (Ceralasertib, Olaparib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what medical application is ATR Kinase Inhibitor AZD6738 most frequently used?
"ATR Kinase Inhibitor AZD6738 is a therapeutic option commonly used after chemotherapy. Additionally, it can be prescribed to address myocardial scintigraphy, coronary artery disease (CAD), and lack of physical activity."
What objectives does this research endeavor hope to accomplish?
"This clinical trial will span up to 2.5 years and evaluate Composite [Prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) Patient Response Rate as its primary outcome measure. Secondary endpoints encompass the calculation of Progression-free survival (PFS) rate over time, Number of treatment-related adverse events (AEs), and an assessment of Prostate Cancer Patient Response Rate using PCWG3 criteria for PSA50 response rate."
What is the aggregate number of participants involved in this investigation?
"Affirmative. As evidenced on clinicaltrials.gov, this medical research was first posted to the public record on January 17th 2019 and has been actively recruiting since then. Currently, 59 patients are needed from one site for enrollment in the trial."
Is this the inaugural research of its kind?
"Since 2005, the ATR Kinase Inhibitor AZD6738 has been under investigation. Initially sponsored by AstraZeneca in a 98-subject study, this drug achieved Phase 1 approval shortly afterwards and today there are 208 active trials taking place across 1472 cities and 59 nations."
Has there been any prior research on the efficacy of ATR Kinase Inhibitor AZD6738?
"Currently, there are 208 clinical trials researching ATR Kinase Inhibitor AZD6738. Of these active studies, 28 have entered the Phase 3 stage of development. Although most tests for this treatment take place in Houston Texas, 9421 other sites across the world are offering trial participants access to ATR Kinase Inhibitor AZD6738."
Has regulatory approval been granted to utilize ATR Kinase Inhibitor AZD6738?
"Although ATR-Kinase Inhibitor AZD6738 is still in Phase 2, which means there is limited evidence backing its efficacy and some supportive of safety, the Power team has rated it a score of 2."
Are there still open slots available to join this clinical experiment?
"Affirmative. Information provided on clinicaltrials.gov states that this investigation is currently seeking participants, having been made available since January 17th 2019 and last updated July 7th 2022. 59 eligible patients need to be enrolled across a single clinical site."
Share this study with friends
Copy Link
Messenger